INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2009

Chondroitins 4 and 6 sulfate significantly reduced joint space width loss and improved pain faster than placebo in patients with knee osteoarthritis over 2 years.

In an international trial, 622 patients with knee osteoarthritis were randomized to receive 800 mg chondroitins 4 and 6 sulfate (CS) or placebo once daily for 2 years. Intent-to-treat analysis showed a significant reduction in minimum joint space width (JSW) loss in the CS group (-0.07 +/- 0.03 mm) compared to placebo (-0.31 +/- 0.04 mm; P < 0.0001). The proportion of patients with radiographic progression >= 0.25 mm was lower with CS (28% vs. 41%, P < 0.0005; relative risk reduction 33%), and pain improved significantly faster in the CS group (P < 0.01) with no differences in safety.

Study type
Randomized, double-blind, placebo-controlled trial
Who was studied
622 patients with knee osteoarthritis
What was measured
Loss in minimum joint space width (JSW) over 2 years, radiographic progression, pain, and safety

THE PAPER

Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial.

Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY. Arthritis Rheum, 2009.

PubMed 19180484 ↗DOI 10.1002/art.24255 ↗

Bones & muscles

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.